Washington State, USA-based CombiMatrix that it has obtained commitments from a group of select investors to purchase up to $8.25 million of its common stock and warrants in a registered direct offering. Under the terms of the transaction, the company will sell around 1.1 million units for $7.50 per unit. Each unit will consist of one share of CombiMatrix common stock and one warrant, each warrant to purchase one share of common stock at an exercise price of $9.00 per share.
The warrants may be exercised beginning six months after the offering and have a term of five years. The warrants will be callable under certain conditions. The closing of the offering is expected to take place on or about May 1, subject to the satisfaction of customary closing conditions. The units are being offered and sold by the firm pursuant to an effective shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission. Proceeds from the offering, net of placement agent fees and expenses, are expected to be approximately $7.57 million. Emerging Growth Equities served as the placement agent for the offering, and The Benchmark Co acted as a selected dealer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze